Risk of Seizure after Naloxone Therapy in Acute Tramadol Poisoning: A Systematic Review with Meta-Analysis.

Meta-analysis naloxone therapy poisoning review tramadol overdose

Journal

International journal of preventive medicine
ISSN: 2008-7802
Titre abrégé: Int J Prev Med
Pays: Iran
ID NLM: 101535380

Informations de publication

Date de publication:
2019
Historique:
received: 14 07 2018
accepted: 07 10 2018
entrez: 6 3 2020
pubmed: 7 3 2020
medline: 7 3 2020
Statut: epublish

Résumé

Many studies have focused on the relationship between naloxone and seizure in tramadol poisoning but the results are in conflict. We performed a meta-analysis study to see whether naloxone prevents or increase the risk of seizure in tramadol poisoning. Bibliographic literature searches were conducted in the ISI Web of Science, Excerpta Medica Database (EMBASE), PubMed, and Cochrane from January 1990 to December 2017 for relevant articles. Pooled data were analyzed by calculating odds ratios (ORs) with 95% confidence intervals (CIs). The outcome includes seizure. To investigate the publication bias, Begg's and Egger's tests were used along with funnel plot as a graphical test. Seven studies met the inclusion criteria. The meta-analysis showed Naloxone therapy did not increase the risk of seizure significantly in the treatment of acute tramadol poisoning. We suggest considering the risk/benefit when administration naloxone, especially for the seizure risk factors including previous history of seizure, tramadol misuse, and co-ingestion.

Sections du résumé

BACKGROUND BACKGROUND
Many studies have focused on the relationship between naloxone and seizure in tramadol poisoning but the results are in conflict. We performed a meta-analysis study to see whether naloxone prevents or increase the risk of seizure in tramadol poisoning.
METHODS METHODS
Bibliographic literature searches were conducted in the ISI Web of Science, Excerpta Medica Database (EMBASE), PubMed, and Cochrane from January 1990 to December 2017 for relevant articles. Pooled data were analyzed by calculating odds ratios (ORs) with 95% confidence intervals (CIs). The outcome includes seizure. To investigate the publication bias, Begg's and Egger's tests were used along with funnel plot as a graphical test.
RESULTS RESULTS
Seven studies met the inclusion criteria. The meta-analysis showed
CONCLUSIONS CONCLUSIONS
Naloxone therapy did not increase the risk of seizure significantly in the treatment of acute tramadol poisoning. We suggest considering the risk/benefit when administration naloxone, especially for the seizure risk factors including previous history of seizure, tramadol misuse, and co-ingestion.

Identifiants

pubmed: 32133101
doi: 10.4103/ijpvm.IJPVM_268_18
pii: IJPVM-10-183
pmc: PMC6826754
doi:

Types de publication

Journal Article

Langues

eng

Pagination

183

Informations de copyright

Copyright: © 2019 International Journal of Preventive Medicine.

Déclaration de conflit d'intérêts

There are no conflicts of interest.

Références

Basic Clin Pharmacol Toxicol. 2008 Sep;103(3):262-6
pubmed: 18684224
Ann Pharmacother. 2015 Dec;49(12):1311-6
pubmed: 26369569
J Med Toxicol. 2009 Jun;5(2):63-7
pubmed: 19415589
Caspian J Intern Med. 2012 Summer;3(3):484-7
pubmed: 24009919
Subst Use Misuse. 2010 Nov;45(13):2162-71
pubmed: 20394504
J Med Toxicol. 2011 Sep;7(3):183-8
pubmed: 21735309
Naunyn Schmiedebergs Arch Pharmacol. 2010 Jan;381(1):11-9
pubmed: 20012267
Clin Toxicol (Phila). 2018 Aug;56(8):737-743
pubmed: 29148295
Emerg Med J. 2010 Dec;27(12):928-30
pubmed: 20378740
Clin Pharmacokinet. 2004;43(13):879-923
pubmed: 15509185
Clin Toxicol (Phila). 2015 Jul;53(6):545-50
pubmed: 25901965
J Toxicol Clin Toxicol. 1997;35(4):361-4
pubmed: 9204095
Iran J Med Sci. 2017 Jul;42(4):327-346
pubmed: 28761199
Addiction. 2018 Mar;113(3):464-472
pubmed: 28841781
J Addict. 2017;2017:6716929
pubmed: 29435382
J Addict Med. 2017 Nov/Dec;11(6):483-488
pubmed: 28858889
J Med Toxicol. 2007 Mar;3(1):15-9
pubmed: 18072153
Clin Toxicol (Phila). 2010 May;48(4):337-41
pubmed: 20367390
Forensic Sci Int. 2007 Dec 20;173(2-3):107-11
pubmed: 17350197
J Pharmacol Exp Ther. 1975 Mar;192(3):538-41
pubmed: 1120955
Ann Pharmacother. 2005 Jun;39(6):1039-44
pubmed: 15870139
Int J Prev Med. 2014 Mar;5(3):302-7
pubmed: 24829714
Psychiatry (Edgmont). 2009 Apr;6(4):17-21
pubmed: 19724727
Res Pharm Sci. 2015 Nov-Dec;10(6):544-52
pubmed: 26779274
Clin Toxicol (Phila). 2018 Aug;56(8):765-772
pubmed: 29322813
Hum Exp Toxicol. 2008 Mar;27(3):201-5
pubmed: 18650251
Psychopharmacology (Berl). 2010 Sep;211(4):457-66
pubmed: 20589494
Am J Emerg Med. 2013 Jan;31(1):26-31
pubmed: 22809771
Pharmacotherapy. 2000 Jun;20(6):629-34
pubmed: 10853617

Auteurs

Nastaran Eizadi-Mood (N)

Department of Clinical Toxicology, Isfahan Clinical Toxicology Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.

Maliheh Ghandehari (M)

Department of Clinical Toxicology, Isfahan University of Medical Sciences, Isfahan, Iran.

Marjan Mansourian (M)

Department of Epidemiology and Biostatistics, Health School, Isfahan University of Medical Sciences, Isfahan, Iran.

Ali Mohammad Sabzghabaee (AM)

Isfahan Clinical Toxicology Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.

Shiva Samasamshariat (S)

Department of Epidemiology and Biostatistics, Health School, Isfahan University of Medical Sciences, Isfahan, Iran.

Erfan Sadeghi (E)

Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran.

Classifications MeSH